Related Experiment Video
Updated: Apr 29, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
68Ga DOTANOC PET/CT detects primary malignant insulinoma
Valentina Ambrosini1, Davide Campana, Cristina Nanni
1From the Departments of *Nuclear Medicine, and †Internal Medicine, Sant'Orsola-Malpighi University Hospital, Bologna; and ‡Department of Nuclear Medicine, Santa Maria della Misericordia, Rovigo, Italy.
Malignant insulinoma, a rare pancreatic tumor, often presents with delayed diagnosis due to non-specific symptoms. Somatostatin receptor imaging aids in detecting these aggressive tumors, crucial for effective surgical management.
Area of Science:
- Oncology
- Endocrinology
- Medical Imaging
Background:
- Malignant insulinoma is an exceptionally rare pancreatic neuroendocrine tumor.
- Characterized by aggressive local and distant spread, leading to diagnostic challenges.
- Symptoms often precede tumor detection and can be misattributed, causing diagnostic delays.
Observation:
- Accurate tumor localization is critical for guiding aggressive surgical resection, the primary treatment.
- Benign insulinomas typically show low somatostatin receptor expression, limiting imaging utility.
- Malignant insulinoma variants, however, can be visualized using somatostatin receptor imaging.
Findings:
- Somatostatin receptor imaging demonstrates utility in detecting malignant insulinoma.
- This imaging modality assists in identifying aggressive tumor forms.
Implications:
- Improved diagnostic accuracy for malignant insulinoma through somatostatin receptor imaging.
- Facilitates timely and appropriate surgical intervention for this rare pancreatic cancer.
- Enhances management strategies for patients with aggressive pancreatic neuroendocrine tumors.
More Related Videos
15:18Near Infrared Optical Projection Tomography for Assessments of β-cell Mass Distribution in Diabetes Research
Published on: January 12, 2013
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018